Akebia Therapeutics Inc (AKBA) was Initiated by Brean Capital to “Buy”. Brean Capital advised their investors in a research report released on Sep 29, 2016.
On the company’s financial health, Akebia Therapeutics Inc reported $-0.40 EPS for the quarter, beating the analyst consensus estimate by $ 0.11 according to the earnings call on Aug 11, 2015. Analyst had a consensus of $-0.51.During the same quarter in the previous year, the company posted $-0.39 EPS.
Akebia Therapeutics Inc opened for trading at $9 and hit $9.25 on the upside on Tuesday, eventually ending the session at $9.09, with a gain of 1.22% or 0.11 points. The heightened volatility saw the trading volume jump to 89,350 shares. Company has a market cap of $346 M.
In a different news, on Jul 6, 2016, Michel Dahan (SVP, Chief Business Officer) sold 1,402 shares at $7.47 per share price. According to the SEC, on Jul 6, 2016, Nicole R. Hadas (SVP, General Counsel, Sec.) sold 1,557 shares at $7.47 per share price. On Oct 5, 2015, Duane Nash (director) sold 996 shares at $8.65 per share price, according to the Form-4 filing with the securities and exchange commission.
Akebia Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease. The Company’s lead product candidate AKB-6548 is being developed as a once-daily oral therapy. It has completed a Phase IIb study demonstrating that AKB-6548 can raise hemoglobin levels in non-dialysis patients with anemia related to chronic kidney disease (CKD). The Company is also conducting a Phase II study for the treatment of anemia in patients undergoing dialysis. The Company’s preclinical candidate AKB-6899 is a small molecule with minor structural differences from its lead compound AKB-6548. AKB-6899 is being developed for the treatment of certain cancers.